Lemaitre Vascular Inc (LMAT) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Lemaitre Vascular Inc (LMAT) stock forecast summary
On Oct. 16, 2026, LMAT is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5184 stocks scored that day.
Lemaitre Vascular Inc is a small-cap company with a market capitalization of $1.85B. It ranks number 27 by market capitalization among the 60 Surgical & Medical Instruments & Apparatus issuers in our coverage with a current forecast.
For LMAT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 8.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 20.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, LMAT included.
Follow LMAT freeLMAT price chart and AI forecast
How LMAT ranks among 5184 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Lemaitre Vascular Inc (LMAT) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Surgical & Medical Instruments & Apparatus peers listed below that report each metric.
Valuation & Market
| Metric | LMAT | Rank |
|---|---|---|
| Market Cap | $1.85B | 27/60 |
| P/E Ratio | 30.38x | 13/25 |
| P/B Ratio | 4.40x | 28/55 |
| Dividend Yield | 1.11% | 7/10 |
| EPS | $2.66 | – |
| Book Value/Share | $18.38 | – |
| Revenue/Share | $11.48 | – |
| FCF/Share | $3.23 | – |
Profitability & Margins
| Metric | LMAT | Rank |
|---|---|---|
| ROE | 15.6% | 12/41 |
| ROA | 10.2% | 9/44 |
| ROIC | 12.7% | 14/53 |
| Gross Margin | 72.9% | 18/53 |
| Operating Margin | 29.5% | 4/54 |
| Net Margin | 25.0% | 3/43 |
| EBT Margin | 32.3% | 5/54 |
| Tax Rate | 22.5% | – |
Financial Health
| Metric | LMAT | Rank |
|---|---|---|
| Current Ratio | 16.31x | 2/59 |
| Quick Ratio | 15.14x | 1/55 |
| D/E Ratio | 0.52x | 30/56 |
| Financial Leverage | 1.52x | 29/54 |
| Interest Coverage | 15.7x | 7/48 |
| Working Capital | $458M | 22/59 |
Cash Flow
| Metric | LMAT | Rank |
|---|---|---|
| Operating Cash Flow | $83M | 23/55 |
| Free Cash Flow | $74M | 18/50 |
| Capital Spending | -$9M | 19/50 |
| OCF Growth YoY | 41.2% | 10/33 |
| FCF Growth YoY | 41.1% | 8/25 |
| FCF/Sales | 28.1% | 4/49 |
| CapEx/Sales | 3.5% | 27/49 |
Operational Efficiency
| Metric | LMAT | Rank |
|---|---|---|
| Asset Turnover | 0.41x | 43/50 |
| Receivables Turnover | 7.3x | 12/51 |
| Inventory Turnover | 2.0x | 25/51 |
| Fixed Assets Turnover | 8.9x | 21/52 |
| Days Sales Outstanding | 50 days | 40/51 |
| Days Inventory | 180 days | 27/51 |
| Payables Period | 17 days | 46/46 |
| Cash Conversion Cycle | 213 days | 17/42 |
Income Statement
| Metric | LMAT | Rank |
|---|---|---|
| Total Revenue | $262M | 35/52 |
| Operating Income | $77M | 17/55 |
| Net Income | $66M | 16/44 |
| R&D Expense | $15M | 46/53 |
| SG&A Expense | $114M | 39/53 |
| Cost of Goods Sold | $71M | 35/53 |
Dividend & Shareholder Information
| Metric | LMAT | Rank |
|---|---|---|
| Dividends Per Share | $0.90 | – |
| Payout Ratio | 33.8% | 6/8 |
| Shares Outstanding | 23M | – |
| Net Income Growth | 39.4% | 7/19 |
| EPS Growth | 32.3% | 7/21 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $488M | 76.2% of assets |
| Cash & Short-term Investments | $27M | 4.2% of assets |
| Accounts Receivable | $36M | 5.6% of assets |
| Inventory | $35M | 5.5% of assets |
| Total Liabilities | $220M | 34.4% of assets |
| Short-term Debt | $27M | 4.2% of assets |
LMAT quarterly financials and insider trading
Lemaitre Vascular Inc (LMAT) industry peers
Companies classified under the same SEC industry code as Lemaitre Vascular Inc (Surgical & Medical Instruments & Apparatus): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| LMAT Lemaitre Vascular Inc | ▶ | $1.85B |
| SYK Stryker Corp | ▼ | $113.02B |
| MMM 3m Co | ▶ | $84.97B |
| BSX Boston Scientific Corp | ▼ | $64.33B |
| BDX Becton Dickinson & Co | ▼ | $52.23B |
| MDLN Medline Inc. | ▶ | $47.28B |
| RMD Resmed Inc | ▼ | $34.47B |
| DXCM Dexcom Inc | ▼ | $32.47B |
| WST West Pharmaceutical Services Inc | ▼ | $27.03B |
| SOLV Solventum Corp | ▼ | $14.61B |
| BAX Baxter International Inc | ▼ | $13.07B |
| PEN Penumbra Inc | ▼ | $12.64B |
| GMED Globus Medical Inc | ▼ | $10.30B |
| PODD Insulet Corp | ▼ | $9.79B |
| GKOS Glaukos Corp | ▲ | $9.72B |
| TFX Teleflex Inc | ▼ | $5.53B |
| HAE Haemonetics Corp | ▶ | $5.38B |
| MMSI Merit Medical Systems Inc | ▼ | $5.33B |
| STVN Stevanato Group S.P.A. | ▲ | $5.16B |
| MMED Minimed Group, Inc. | ▲ | $4.92B |
| HTFL Heartflow, Inc. | ▲ | $4.20B |
| ICUI Icu Medical Inc/De | ▼ | $4.08B |
| IRTC Irhythm Holdings, Inc. | ▼ | $3.58B |
| PLSE Pulse Biosciences, Inc. | ▲ | $3.17B |
| ATRC Atricure, Inc. | ▲ | $2.85B |
| UFPT Ufp Technologies Inc | ▼ | $2.26B |
| INSP Inspire Medical Systems, Inc. | ▲ | $1.99B |
| NVCR Novocure Ltd | ▲ | $1.64B |
| KMTS Kestra Medical Technologies, Ltd. | ▲ | $1.62B |
| ATEC Alphatec Holdings, Inc. | ▲ | $1.62B |
| TNDM Tandem Diabetes Care Inc | ▲ | $1.13B |
| IRMD Iradimed Corp | ▶ | $1.13B |
| DRTS Alpha Tau Medical Ltd. | ▶ | $1.08B |
| AORT Artivion, Inc. | ▶ | $1.06B |
| IART Integra Lifesciences Holdings Corp | ▶ | $1.03B |
| PRCT Procept Biorobotics Corp | ▲ | $1.01B |
| BVS Bioventus Inc. | ▶ | $908M |
| SIBN Si-Bone, Inc. | ▶ | $882M |
| BBNX Beta Bionics, Inc. | ▲ | $863M |
| SGP Spyglass Pharma, Inc. | ▶ | $803M |
| MDXG Mimedx Group, Inc. | ▲ | $646M |
| KIDS Orthopediatrics Corp | ▶ | $573M |
| TCMD Tactile Systems Technology Inc | ▼ | $510M |
| SSII Ss Innovations International, Inc. | ▲ | $507M |
| DCTH Delcath Systems, Inc. | ▲ | $497M |
| ANGO Angiodynamics Inc | ▲ | $473M |
| SGHT Sight Sciences, Inc. | ▲ | $456M |
| BWAY Brainsway Ltd. | ▶ | $448M |
| CERS Cerus Corp | ▶ | $439M |
| NPCE Neuropace Inc | ▶ | $420M |
| RCEL Avita Medical, Inc. | ▲ | $403M |
| OFIX Orthofix Medical Inc. | ▼ | $382M |
| CARL Carlsmed, Inc. | ▲ | $366M |
| EMBC Embecta Corp. | ▶ | $355M |
| OBIO Orchestra Biomed Holdings, Inc. | ▲ | $328M |
| CLPT Clearpoint Neuro, Inc. | ▲ | $277M |
| MOBI Mobia Medical, Inc. | ▼ | $269M |
| ANIK Anika Therapeutics, Inc. | ▶ | $267M |
| TMCI Treace Medical Concepts, Inc. | ▲ | $252M |
| OSUR Orasure Technologies Inc | ▲ | $249M |
Where LMAT sits on the market map
Lemaitre Vascular Inc (LMAT) stock news
Loading...
Lemaitre Vascular Inc (LMAT) stock forecast FAQ
What is the Lemaitre Vascular Inc (LMAT) stock forecast?
On Oct. 16, 2026, LMAT is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5184 stocks scored that day.
How accurate are Lemaitre Vascular Inc stock predictions?
For LMAT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 8.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 20.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Lemaitre Vascular Inc forecasts updated?
Lemaitre Vascular Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Lemaitre Vascular Inc's industry peers?
60 issuers in our coverage, LMAT included, share the SEC industry code Surgical & Medical Instruments & Apparatus. The largest are: Stryker Corp (SYK), 3m Co (MMM), Boston Scientific Corp (BSX), Becton Dickinson & Co (BDX), Medline Inc. (MDLN), Resmed Inc (RMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.